Last reviewed · How we verify
recAP
recAP is a recombinant alkaline phosphatase that breaks down lipopolysaccharide (LPS) and other inflammatory mediators to reduce systemic inflammation.
recAP is a recombinant alkaline phosphatase that breaks down lipopolysaccharide (LPS) and other inflammatory mediators to reduce systemic inflammation. Used for Sepsis-associated organ dysfunction, Inflammatory bowel disease (Crohn's disease and ulcerative colitis).
At a glance
| Generic name | recAP |
|---|---|
| Also known as | Recombinant Alkaline Phosphatase |
| Sponsor | AM-Pharma |
| Drug class | Recombinant enzyme |
| Target | Lipopolysaccharide (LPS) and pathogen-associated molecular patterns (PAMPs) |
| Modality | Biologic |
| Therapeutic area | Immunology / Gastroenterology / Critical Care |
| Phase | FDA-approved |
Mechanism of action
recAP (recombinant intestinal alkaline phosphatase) dephosphorylates lipopolysaccharide and other pathogen-associated molecular patterns, reducing their pro-inflammatory signaling through TLR4 and other pattern recognition receptors. By decreasing bacterial endotoxin-driven inflammation, it mitigates systemic inflammatory responses implicated in conditions such as sepsis and inflammatory bowel disease.
Approved indications
- Sepsis-associated organ dysfunction
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
Common side effects
- Injection site reactions
- Hypersensitivity reactions
Key clinical trials
- Mindfulness-Based Peak Performance, Endurance Performance Under Pressure, Performance-relevant Mental Attributes (NA)
- Intensive Prevention Program After Decompensated Heart Failure (NA)
- Functional Analysis of BRCAness (PHASE2)
- Virtual Reality-Based Mindfulness for Caregivers of Psychiatric Patients (NA)
- Weight Bias Reducation Intervention With Nursing Students Using Simulation: The BRAVE Study (NA)
- The RECAP2 Study: Midazolam and Psilocybin (PHASE1)
- Pilot Study of the Liver Live Donor Champion Program (NA)
- Implementation of the Live Donor Champion Program (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recAP CI brief — competitive landscape report
- recAP updates RSS · CI watch RSS
- AM-Pharma portfolio CI